In a first, WHO approves medicine to make breast cancer treatment cheaper

The World Health Organization (WHO) announced Wednesday that it had for the first time approved a "biosimilar" medicine -- one derived from living sources rather than chemicals -- to make breast cancer treatment affordable to women globally.

The trastuzumab drug has shown "high efficacy" in curing early stage breast cancer and in some cases more advanced forms of the disease, the WHO said in a statement.

But the annual cost of the original drug is an average (of) $20,000, "a price that puts it out of reach of many women and healthcare systems in most countries," the statement added.

However, the biosimilar version of trastuzumab is generally 65 per cent cheaper than the original.

"With this WHO listing, and more products expected in the prequalification pipeline, prices should decrease even further," the WHO said. Read Complete Article